InspireMD Inc(NSPR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 7:59 PM ET (Korea 11/4 09:59)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.65 | Insider Own | 28.87% | Shs Outstand | 46.9M | Perf Week | 44.59% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | 21.2% | Insider Trans | 1.77% | Shs Float | 33.1M | Perf Month | 13.41% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.15 | Inst Own | 40.48% | Short Float | 0.24% | Perf Quarter | -8.63% |
| Income | -0.05B | P/S | 2.82 | EPS this Y | 19.3% | Inst Trans | -4.19% | Short Ratio | 0.55 | Perf Half Y | -40.19% |
| Sales | 0.01B | P/B | 0.98 | EPS next 5Y | - | ROA | -134.6% | Short Interest | 0.08M | Perf YTD | -63.04% |
| Book/sh | 0.67 | P/C | 1.01 | EPS past 3/5Y | 31.4% 35.83% | ROE | -202.81% | 52W High | -72.59% ($2.40) | Perf Year | -71.27% |
| Cash/sh | 0.65 | P/FCF | - | Sales past 3/5Y | 20.19% 29.29% | ROIC | -156.76% | 52W Low | 54.65% ($0.43) | Perf 3Y | -80.9% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 22.08% | Gross Margin | 18.05% | Volatility(W/M) | 16.69% 14.78% | Perf 5Y | -84.7% |
| Dividend TTM | - | EV/Sales | 0.29 | Sales Y/Y TTM | 53.42% | Oper. Margin | -494.03% | ATR (14) | 0.07 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 3.52 | EPS Q/Q | 34.37% | Profit Margin | -484.11% | RSI (14) | 66.49 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.8 | Sales Q/Q | -0.39% | SMA20 | 36.88% ($0.48) | Beta | 0.88 | Target Price | $3.33 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 2026/11/12 | SMA50 | 0.85% ($0.65) | Rel Volume | 3.81 | Prev Close | $0.54 |
| Employees | 127 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | 15% 28.05% | SMA200 | -37.95% ($1.06) | Avg Volume(3M) | 0.15M | Price | $0.66 |
| IPO | 2011/4/11 | Option/Short | Yes/Yes | Trades | 568 | Volume | 557,217 | Change | 22.06% |
A global medical device company developing innovative carotid stent systems for stroke prevention, built on its proprietary 'MicroNet®' technology. Through its next-generation 'CGuard™' stent, the company is dramatically improving embolic protection during procedures and enhancing patient safety.
Over the past 1 year, on the lower side
73% below its 1-year high.
Traded more than usual. That is 381% of its average volume.
Next earnings report: November 12
8 days to go.
NSPR has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +19.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $282. Peers typically go for $145.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -84.7%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 40.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% It ranks #105 of 140 in the industry
Based on market cap of $31M.
FAQ
What kind of company is NSPR?
NSPR belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of NSPR?
The market cap of NSPR is approximately $31M, ranking 5,069 within its sector.
What is the 52-week high and low for NSPR?
NSPR has recorded a 52-week high of $2.40 and a low of $0.43.
